| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005156612 |
| P356 | DOI | 10.1007/S10637-014-0152-Z |
| P698 | PubMed publication ID | 25152245 |
| P2093 | author name string | Takao Yamori | |
| Dexin Kong | |||
| Shingo Dan | |||
| Kanami Yamazaki | |||
| P2860 | cites work | Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. | Q53423714 |
| UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers | Q57577896 | ||
| ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms | Q80824161 | ||
| Guidelines for the use and interpretation of assays for monitoring autophagy | Q21996341 | ||
| NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 | ||
| JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs | Q27025525 | ||
| The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer | Q27651832 | ||
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor | Q27676347 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Signalling through the lipid products of phosphoinositide-3-OH kinase | Q28241516 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Role of autophagy in cancer | Q29620348 | ||
| Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis | Q31983511 | ||
| Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel | Q33178811 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy | Q37212251 | ||
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 | Q37281824 | ||
| Advances in development of phosphatidylinositol 3-kinase inhibitors | Q37581693 | ||
| ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system | Q37728043 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations | Q39338784 | ||
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models | Q39706127 | ||
| Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. | Q39744205 | ||
| Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
| Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor | Q39856372 | ||
| A new evaluation method for quantifying PI3K activity by HTRF assay | Q39925116 | ||
| Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines | Q40093122 | ||
| Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor | Q40290597 | ||
| Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines | Q40336515 | ||
| PI3K: downstream AKTion blocks apoptosis | Q41351876 | ||
| Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines | Q41679901 | ||
| Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations | Q43041602 | ||
| Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. | Q46047974 | ||
| Frequent mutation of the PIK3CA gene in ovarian and breast cancers | Q48924016 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1134-1143 | |
| P577 | publication date | 2014-08-26 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. | |
| P478 | volume | 32 |
| Q27315948 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer |
| Q33889083 | Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells |
| Q37587308 | Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy |
| Q39097109 | Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma |
| Q36911063 | In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells |
| Q37696147 | Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells |
| Q36950643 | Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway |
| Q33709955 | Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5 |
| Q92055924 | Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC) |
| Q49349544 | The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo |
| Q100415901 | The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells |
| Q37190204 | ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells |
Search more.